TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03996148
Drug: Remifentanil, Dexmedetomidine, and Desflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Dexmedetomidine - titratable; initial starting dose 0.5 mcg/kg/hr Desflurane 0.5 MAC
Study: NCT03996148
Drug: Remifentanil and Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Desflurane - titratable
Study: NCT01103726
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablets, single dose
Study: NCT01103726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablets, single dose
Study: NCT01996943
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6% volume/volume ethanol in 0.45% saline solution.
Study: NCT01996943
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo with be 0.45% saline solution (half normal saline).
Study: NCT02504671
Drug: GSK3196165
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3196165 is supplied as liquid and will be administered as SC injection.
Study: NCT02504671
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid will be supplied as capsule, tablet or liquid and will be administered orally.
Study: NCT02504671
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is supplied as liquid as sterile 0.9% weight by volume (w/v) sodium chloride solution and will be administered as SC injection
Study: NCT03049605
Drug: Only medical treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fifteen patients with diabetic peripheral neuropathy were treated with antidiabtic drugs and lyrica 150 milligram daily
Study: NCT00069511
Drug: UT-231B
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03222583
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet for oral administration
Study: NCT03573505
Drug: BG00011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT00811356
Drug: GSK932121; Rosiglitazone; Rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK932121 is the study drug that will be tested in all parts of this study as described above. Rosiglitazone and rosuvastatin will only be tested in the drug-drug interaction substudy.
Study: NCT03829696
Drug: Mifeprex® (Mifepristone 200 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Mifeprex® (mifepristone 800 mcg) from a clinician when they are not pregnant. Participants who have an unintended pregnancy during the study period and would like to have a medication abortion will consult with a clinician for an over-the-phone evaluation of contraindications and gestational age. Participants who take the medications will be evaluated again in-person at a subsequent follow-up visit.
Study: NCT02262793
Drug: ASA/ER-DP
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00468728
Drug: PAR-101/OPT-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules
Study: NCT02982798
Drug: Metformin + Rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of Metformin + Rosuvastatin
Study: NCT01858948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar in shape and color to Omega supplements
Study: NCT01016093
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg adjusted dose based on renal function IV 15-minute infusion every 3 months for a total of one year ( 4 doses ) beginning as soon as possible after randomization.
Study: NCT01016093
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00132171
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00505089
Drug: ACZ885
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01998672
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinking solution
Study: NCT04657926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT03514641
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inactive) tablet to match the active drug
Study: NCT01857141
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients in the control groups received the equivalent volume of normal saline.
Study: NCT02047175
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 20mg 1T PO, QD for 5days
Study: NCT02047175
Drug: Telmisartan/S-Amlodipine + Rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 9days
Study: NCT01345175
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pt will receive placebo bid for 4 weeks. Patients will at this stage on a volunteer basis be asked to submit stool samples and undertake a breath test. Patients will receive the respective treatment for four weeks. Following cessation of treatment all patients will be assessed using the BFI and respective patients will have repeat stool sampling and breath testing. Patients will then have these tests repeated 4 weeks later. This corresponds to 8 weeks after the start of the trial. For those patients not undertaking stool and breath testing, they will be reminded by phone, mail or email to fill out the BFI. Before and during the trial patients will be asked to fill out a weekly stool diary to evaluate trends on bowel function.
Study: NCT02998970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral tablet once daily.
Study: NCT00324766
Drug: placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 h, infusion
Study: NCT01145430
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02906930
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration once daily.
Study: NCT03347422
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.)
Study: NCT03097835
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia will be bilaterally applied to the mid-face region for 20 minutes
Study: NCT03683524
Drug: Current ART
Approvals — FDA: no, EMA: no, PMDA: no
Description: To continue with their current ART
Study: NCT04383236
Drug: Oracure oral gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sixty adult (group A) and 60 children patients (group B) with diagnosis of minor RAS were included. Both groups were divided into two subgroups, AI and BI (test subgroups) and AII and BII (control subgroups). For control subgroups, oracure gel were consecutively applied twice daily, for five days. The size and pain level of ulcers were recorded on treatment days 0, 3 and 5. The outbreak frequency of RAS within 6 months was investigated for all subgroups.
Study: NCT04198636
Drug: LY01011
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY01011 injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
Study: NCT04198636
Drug: Xgeva 120 MG in 1.7 ML Injection
Normalized name: Xgeva 120 MG in 1.7 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
Study: NCT03679052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient received two placebo tablets for mirtazapine and clonidine orally with sips of water 2 h preoperatively.
Study: NCT02868918
Drug: glass ionomer cement
Normalized name: Cement
Approvals — FDA: no, EMA: no, PMDA: no
Description: high viscosity glass ionomer used as a base material
Study: NCT03402776
Drug: 4th dose of hexavalent vaccine 1 month after the 3rd dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4th dose of hexavalent vaccine 1 month after the 3rd dose
Study: NCT00784186
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo resembling mifepristone taken 24 hours before 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
Study: NCT01659866
Drug: gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg/kg intramuscularly 2 hours before the procedure
Study: NCT01659866
Drug: amikacin
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/kg intramuscularly 2 hours before the procedure
Study: NCT01659866
Drug: gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg/kg intravenously 1 hour before the procedure
Study: NCT01659866
Drug: amikacin
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/kg intravenously 1 hour before the procedure
Study: NCT01021358
Drug: ABT-263
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
Study: NCT00658749
Drug: AIR645
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
Study: NCT00658749
Drug: Physiologic saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
Study: NCT02730351
Drug: Placebo via DISKUS / ACCUHALER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered via DISKUS / ACCUHALER, twice daily, once in the morning and once in the evening
Study: NCT02296021
Drug: clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 20mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
Study: NCT00002679
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002679
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00562575
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00755404
Drug: PD Solution
Normalized name: CAPD solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 180 days.
Study: NCT00755404
Drug: PD solution containing L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 180 days.
Study: NCT04101500
Drug: Placebo Tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied only to the control group.
Study: NCT03365752
Drug: General Anesthetics
Normalized name: GENERAL ANESTHETICS,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthetics will be administered intravenously
Study: NCT03751956
Drug: HSK3486
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive an intravenous injection of 0.8 μCi/0.4 mg/kg of \[14C\]HSK3486 emulsion injection (i.e., a subject with the body weight of 60 kg is administered with a radiation dose of 48 μCi).
Study: NCT02633488
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 12 week single blind placebos
Study: NCT00002785
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002785
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002785
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002785
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002785
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03335293
Drug: 100 mcg Epinephrine
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study will evaluate the optimal dose of epinephrine as an adjunct to spinal doses of 1.6 mL hyperbaric bupivacaine + 20 mcg preservative free fentanyl + 150 mcg preservative-free morphine.
Study: NCT03335293
Drug: 200 mcg Epinephrine
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study will evaluate the optimal dose of epinephrine as an adjunct to spinal doses of 1.6 mL hyperbaric bupivacaine + 20 mcg preservative free fentanyl + 150 mcg preservative-free morphine.
Study: NCT03417193
Drug: opioid free Anesthesia vs Opioid based Anesthesia
Normalized name: ABT-925 anhydrous free base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compare the opioid based anesthesia with Fentanyl and Remifentanyl to opioid free anesthesia with dexmedetomidine and lidocaine and their effect on postoperative pain.
Study: NCT01561508
Drug: gamma-amino-butyric acid
Normalized name: gamma-Amino-beta-(p-chlorophenyl)butyric acid
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gamma-amino butyric acid will be administered orally at a dose of 80mg/kg/day divided BID for one year.
Study: NCT03884452
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets taken orally once daily in the morning or evening
Study: NCT00987389
Drug: Glucocorticoids [Standard Dose]
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a standard regimen.
Study: NCT00987389
Drug: Glucocorticoids [Reduced Dose]
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a reduced regimen.
Study: NCT01682863
Drug: QAB149
Approvals — FDA: no, EMA: no, PMDA: no
Description: QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI
Study: NCT01682863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To mimic QAB149
Study: NCT03127644
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suspension administered orally placebo three times daily for 48 hours.
Study: NCT01617694
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00134693
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04126213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single dose of placebo (NaCl solution) administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
Study: NCT00009009
Drug: immunosuppressive regimen designed to complement HAART
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03003949
Drug: Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release
Normalized name: Estradiol Patch, 0.1 mg/24 hours weekly transdermal film, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal Estradiol worn daily for 16 weeks (patch changed every 7 days).
Study: NCT03003949
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo patches to be worn every day for 16 weeks (patch changed every 7 days).
Study: NCT02987101
Drug: Adipose-Derived Regenerative Cells
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cells isolated from adipose-derived tissue will be injected locally around and under the wound.
Study: NCT01379001
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM or PO placebo
Study: NCT02400242
Drug: ACY-241
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation up to 480 mg administered orally on Days 1-21 of a 28 day cycle.
Study: NCT00399256
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02092896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
Study: NCT02092896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
Study: NCT00663767
Drug: Placebo; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose 1, dose 2
Study: NCT00663767
Drug: Placebo; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose 1
Study: NCT00663767
Drug: ARRY-371797, p38 inhibitor; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose 1: multiple dose levels
Study: NCT00663767
Drug: Placebo; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose 2
Study: NCT00985712
Drug: Huminsulin Regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
Study: NCT04209205
Drug: AIN457 6 mg/kg i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIN457 6 mg/kg delivered by i.v. infusion
Study: NCT04209205
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to AIN457 i.v. infusion
Study: NCT04209205
Drug: AIN457 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIN457 3 mg/kg delivered by i.v. infusion
Study: NCT02415569
Drug: Standard Bowel Prep (2L PEG-ELP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects whose bristol stool forms are type 3 to 7, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
Study: NCT01620099
Drug: Extrafine treatment (Clenilexx(R) or Foster(R))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following the initial evaluation (cross-sectional) patients will be switched to an extrafine equipotent dose of the same compound (extrafine beclomethasone dipropionate - Clenilexx(R) - if the patient was on ICS) or combination (extrafine beclomethasone dipropionate/formoterol - Foster(R) - if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
Study: NCT03915067
Drug: BOTOX® purified neurotoxin complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOTOX® superficial intramuscular injections.
Study: NCT03343613
Drug: LY3381916
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDO-1 inhibitor administered orally
Study: NCT03343613
Drug: LY3300054
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-L1 inhibitor administered IV
Study: NCT03915067
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections.
Study: NCT01033942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
Study: NCT04254939
Drug: CS3007 (BLU-285)
Normalized name: Blu-Kote
Approvals — FDA: no, EMA: no, PMDA: no
Description: A modified 3+3 dose escalation design will be adopted. Each group will enroll 3-6 subjects. Avapritinib will be administered orally at the starting of 200 mg QD. A cycle consists of 28 consecutive days.
Study: NCT04158700
Drug: LY3200882
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3200882 administered orally
Study: NCT02362984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of DLBS1033 will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
Study: NCT02362984
Drug: DLBS1033
Approvals — FDA: no, EMA: no, PMDA: no
Description: DLBS1033 enteric-coated tablets will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
Study: NCT00239655
Drug: MK0812
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01943721
Drug: VISION5 Product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00406042
Drug: prednisolone acetate 1%
Normalized name: PREDNISOLONE ACETATE 1% SUSP,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01882075
Drug: Open loop
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02683265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT01102374
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo monthly
Study: NCT01469702
Drug: prednison and azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients with typical cat-scratch disease will be treated with a 5-day course of prednison and azithromycin.
Study: NCT01469702
Drug: prednison, azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cap Azithromycin 500 mg qd (first day), then 250 mg qd for 4 days and Tab prednison 1 mg/kg/day, not exceeding 60 mg/day, qd, for 5 days.
Study: NCT01469702
Drug: prednison, Azenil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cap Azenil 500 mg qd (first day), then 250 mg qd for 4 days and Tab prednison 1 mg/kg/day, not exceeding 60 mg/day qd, for 5 days.